TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Indonesia’s health ministry has directed food companies to introduce coloured labels indicating nutritional content, within two years. Red and green labels will indicate high and low sugar, salt, and fat content respectively. Companies must revise packaging and validate nutritional content to meet the new labelling requirements, but detailed sanctions for non-compliance have not been informed yet.
Source: shortlink.uk/1nEyC

2. Gujarat Food and Drug Control Administration has reportedly directed all ayurvedic medicine manufacturers to register on the ayudmla.gujarat.gov.in portal and upload complete legacy records, mandating digital compliance for licensing processes across the state. It strengthens regulatory oversight and promotes digital compliance in the ayurvedic sector.
Source: shortlink.uk/1sU3e

3. The Bangalore District Chemists and Druggists Association and other retail pharmacy groups have urged regulators to mandate licensing requirements for e-pharmacies displaying medicines online, similar to physical stores under the Drugs and Cosmetics Act, 1940. This is important as it highlights growing concerns around patient safety, regulatory gaps, and unfair competition. If implemented, e-pharmacy platforms may face stricter compliance, licensing requirements, and potential changes to their marketplace and digital medicine distribution models.
Source: shortlink.uk/1sU3h

4. A leading weight loss drug manufacturer has partnered with OpenAI to deploy artificial intelligence across drug discovery, manufacturing, and operations, while training its workforce globally. The initiative will help to enhance productivity, strengthen competitive positioning in the obesity therapeutics market, and improve overall efficiency without immediate workforce reductions.
Source: shortlink.uk/1nEyI

5. The Bangalore District Chemists and Druggists Association and other retail pharmacy groups have urged regulators to extend licensing norms for medicine display to e-pharmacies, seeking clarity on “offer for sale” under the Drugs and Cosmetics Act. This is important to curb unlicensed digital sales and ensure parity, potentially bringing online platforms under stricter licensing and compliance requirements.
Source: shortlink.uk/1sU3l

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Indian Pharmacopoeia Commission (IPC) has released the draft National Formulary of India (NFI) 2026, inviting stakeholder comments within 45 days of upload of the respective chapters and appendices, ahead of its proposed finalisation. The draft aims to promote rational use of medicines through evidence based prescribing guidance, standardised drug information, and measures to reduce medication errors and antimicrobial resistance.
Source: shortlink.uk/1sKC9

2. The Delhi High Court has directed the discontinuation of the “Olymviq” mark for semaglutide injections on account of its similarity with the “Ozempic” brand. A 30-day transition window has been granted to clear existing stock and shift to the alternative mark “Olymra.” The order reflects heightened judicial scrutiny of pharmaceutical trademarks, particularly in cases involving likelihood of confusion, prompting companies to reassess trademark strategies.
Source: shortlink.uk/1sKCd

3. The Drugs Consultative Committee in its sixty eighth meeting approved recommendations on scheduling of certain medicines, retaining dicyclomine in Schedule H and moving flupentixol, zopiclone, gabapentin and carisoprodol to Schedule H1. This is important as stricter controls will curb misuse and intoxication, improve monitoring and dispensing accountability.
Source: https://shortlink.uk/1sKCi

4. The Central Drugs Standard Control Organisation (CDSCO) reportedly plans to tighten oversight of medicine packaging, emphasizing clear visibility of drug names, strength, and expiry dates. Through stricter inspections and regulatory directions, it aims to reduce medication errors and improve patient safety, prompting pharmaceutical companies to enhance labelling design, printing quality, and compliance standards.
Source: shortlink.uk/1nvq0

5. The Ministry of Environment has amended the Plastic Waste Management Rules, 2016, removing the requirement to declare the percentage of recycled plastic on labels. Instead, packaging must comply with IS 14534:2023 and carry the prescribed marking, simplifying labelling obligations while ensuring adherence to recycling standards.
Source: shortlink.uk/1sKnX

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Health Ministry has directed all manufacturers of high-risk pharma-grade solvents to obtain or register their licences on the ONDLS portal and upload batch-wise details, including quantity, CoA, and vendor information. A list of high-risk solvents has been issued, and State Drug Regulators have been directed to ensure that no batch is sold without compliance to these directions.
Source: urli.info/1iJjN

2. Central Drugs Standard Control Organization (CDSCO) has clarified that manufacturers of risk Class A and B medical devices not listed in its risk classification list must obtain proper risk classification from CDSCO before applying for a manufacturing licence. Investigational medical device manufacturers must also secure prior CDSCO permission before the grant of manufacturing licence.
Source: urli.info/1dXH7

3. India’s Central Drugs Standard Control Organization (CDSCO) has issued a list of Class A non-sterile and non-measuring (NSNM) medical devices which are exempted from licensing requirements. Manufacturers and importers of the listed devices must obtain CDSCO registration as Class A NSNM medical devices under the Medical Devices Rules, 2017.
Source: urli.info/1dXHz

4. The National Company Law Appellate Tribunal has ruled that the Competition Commission of India lacks jurisdiction to investigate alleged anti-competitive conduct involving patented pharmaceutical products, emphasising that the Patents Act, 1970 prevails over the Competition Act, 2002 when the conduct in question arises from the exercise of patent rights.
Source: urli.info/1dXHI

5. The Delhi High Court has upheld the FSSAI’s directive prohibiting companies from using the term “ORS” (Oral Rehydration Solution) on product labels unless the formulation meets prescribed standards. The Court held that public health considerations override commercial claims and that products misleadingly labelled as “ORS” could endanger consumers. While the company may request FSSAI permission to re-label existing stock, the ban itself remains in force.
Source: urli.info/1iJkL